Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study
Name:
s41467-019-14279-8.pdf
Size:
738.0Kb
Format:
PDF
Description:
Final Published Version
Author
Reiman, Eric MAffiliation
Univ ArizonaIssue Date
2020-02-03
Metadata
Show full item recordPublisher
NATURE PUBLISHING GROUPCitation
Reiman, E.M., Arboleda-Velasquez, J.F., Quiroz, Y.T. et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun 11, 667 (2020). https://doi.org/10.1038/s41467-019-14279-8Journal
NATURE COMMUNICATIONSRights
Copyright © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer's dementia, while the APOE2 allele is associated with a lower risk of Alzheimer's dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We generated Alzheimer's dementia odds ratios and other findings in more than 5,000 clinically characterized and neuropathologically characterized Alzheimer's dementia cases and controls. APOE2/2 was associated with a low Alzheimer's dementia odds ratios compared to APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically confirmed group than in more than 24,000 neuropathologically unconfirmed cases and controls. Finding and targeting the factors by which APOE and its variants influence Alzheimer's disease could have a major impact on the understanding, treatment and prevention of the disease.Note
Open access journalISSN
2041-1723PubMed ID
32015339Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1038/s41467-019-14279-8
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.
Related articles
- Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
- Authors: Huang YA, Zhou B, Nabet AM, Wernig M, Südhof TC
- Issue date: 2019 Sep 11
- Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy.
- Authors: Williams T, Bathe T, Vo Q, Sacilotto P, McFarland K, Ruiz AJ, Hery GP, Sullivan P, Borchelt DR, Prokop S, Chakrabarty P
- Issue date: 2023 Jun 19
- Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2.
- Authors: Vandal M, Alata W, Tremblay C, Rioux-Perreault C, Salem N Jr, Calon F, Plourde M
- Issue date: 2014 May
- Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.
- Authors: Dunk MM, Driscoll I, Alzheimer’s Disease Neuroimaging Initiative
- Issue date: 2022
- Apolipoprotein E2 Expression Alters Endosomal Pathways in a Mouse Model With Increased Brain Exosome Levels During Aging.
- Authors: Peng KY, Liemisa B, Pasato J, D'Acunzo P, Pawlik M, Heguy A, Penikalapati SC, Labuza A, Pidikiti H, Alldred MJ, Ginsberg SD, Levy E, Mathews PM
- Issue date: 2024 May